Waverly Advisors LLC Has $16.59 Million Stake in Danaher Corporation $DHR

Waverly Advisors LLC raised its stake in Danaher Corporation (NYSE:DHR) by 12.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,505 shares of the conglomerate’s stock after acquiring an additional 10,029 shares during the quarter. Waverly Advisors LLC’s holdings in Danaher were worth $16,591,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Van Den Berg Management I Inc. grew its holdings in shares of Danaher by 1.2% during the 1st quarter. Van Den Berg Management I Inc. now owns 36,228 shares of the conglomerate’s stock valued at $6,869,000 after purchasing an additional 426 shares during the last quarter. Unisphere Establishment lifted its stake in Danaher by 12.3% in the 1st quarter. Unisphere Establishment now owns 639,000 shares of the conglomerate’s stock valued at $121,154,000 after purchasing an additional 70,000 shares during the last quarter. Dempze Nancy E boosted its position in Danaher by 3.1% in the first quarter. Dempze Nancy E now owns 20,879 shares of the conglomerate’s stock valued at $3,959,000 after buying an additional 636 shares in the last quarter. Entropy Technologies LP bought a new stake in shares of Danaher during the first quarter worth $5,588,000. Finally, Cannell & Spears LLC grew its stake in shares of Danaher by 6.4% during the first quarter. Cannell & Spears LLC now owns 272,505 shares of the conglomerate’s stock worth $50,885,000 after buying an additional 16,427 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 0.2%

Shares of DHR opened at $191.87 on Monday. The company has a market capitalization of $134.88 billion, a PE ratio of 34.08, a PEG ratio of 2.38 and a beta of 0.79. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The stock’s 50-day moving average price is $185.64 and its two-hundred day moving average price is $196.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the prior year, the firm posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. On average, analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio is currently 28.42%.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Citigroup started coverage on Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target for the company. Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday. Piper Sandler started coverage on Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price objective for the company. Finally, Barclays dropped their price objective on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.